Health · Medical Research · 3 hrs ago
Italian study prepares for targeted therapies for TARDP-related ALS
At a live event in Rome, Aisla highlighted research into genetic forms of ALS and the need to connect research with families’ daily lives.
The focus included ALS linked to the TARDP gene, alongside cooperation between Italian clinics and US research institutes.
A study involving eight Italian centers is preparing patients for future targeted therapies.
It followed an initial mapping effort across 26 clinical centers coordinated by a working group of the Italian Society of Neurology.
Fondazione AriSLA contributed €700,000 to support the study.
The aim is to help make patients ready for future molecular treatments, while Aisla also stressed the need for care and support now.
The discussion continues in Milan at the AriSLA scientific conference on November 19 and 20.
An Italian multicentre study is preparing people with TARDP-related ALS for future targeted molecular therapies.
The study involves eight Italian centres and is supported by a €700,000 investment from Fondazione AriSLA.
It followed an initial mapping carried out across 26 clinical centres.
The work was discussed at “La promessa,” a live event promoted by the Italian ALS Association, Aisla, in Rome.
The event opened a three-day programme on the future of research, which continued in Milan on 19 and 20 November.
- Who
- The Italian Tardbp Trial Readiness study involves eight Italian centres and is supported by Fondazione AriSLA.
- What
- It is preparing patients with Tardbp-related ALS for future targeted molecular therapies.
- When
- The study’s dates are not stated. “La promessa” aired on the evening before 19 November 2026.
- Where
- The study involves Italian centres. The event was held at Palazzo dell’Informazione in Rome.
- Why
- To prepare patients for future targeted molecular therapies.
This story does not have two clearly opposing sides.
An initial mapping was conducted across 26 clinical centres.
The work developed into a multicentre study involving eight Italian centres.
The live event “La promessa” was held in Rome and opened a three-day programme on the future of research.
The discussion continued in Milan at the 10th AriSLA Scientific Conference.
- Study name
- Italian Tardbp Trial Readiness
- Centres in study
- 8 Italian centres
- Initial mapping
- 26 clinical centres
- Funding
- €700,000 from Fondazione AriSLA
- Event venue
- Palazzo dell’Informazione, Rome
What people are saying
Our task is to keep together two essential tracks: supporting cutting-edge scientific research, so that advances in genetics soon become treatments accessible to everyone, and ensuring rights, care and concrete relief in local communities today.